Health
FDA says Paxlovid is not linked to COVID-19 rebound
As the U.S. Food and Drug Administration’s independent advisers prepare to discuss the full approval of Pfizer’s COVID-19 antiviral, Paxlovid, agency experts said this week that clinical trial data shows that it is safe and effective for treatment of mild to moderate illness in high-risk adults.
Top Stories
Just the News Spotlight
Just News, No Noise
Trending
- Solar farm the size of 2,500 football fields destroyed in Texas amid growing solar e-waste problem
- Netanyahu changes mind after US cease fire vote, will go ahead with sending delegation to Washington
- Washington state governor signs ‘natural gas ban bill’ into law
- House Democrat unveils plan to keep classified docs from Trump, Menendez
- Tony Bobulinski sues Jessica Tarlov over on-air comments